Whether enabling new approaches to patient safety monitoring
and clinical trials, or improving success rates for regulatory
submissions, artificial intelligence (AI) offers enormous potential to
transform many routine pharmaceutical processes. Marco Anelli at
ProductLife Group discusses the timely and beneficial outcomes of
AI.